SPEAKERS

Timothy Noël
Eindhoven University of Technology
Chairman & Keynote Speaker

Biography
Timothy Noël 
received in 2004 his MSc degree (Industrial Chemical Engineering) from the KaHo Sint-Lieven in Ghent. He then moved to Ghent University to obtain a PhD at the Laboratory for Organic and Bioorganic Synthesis (2005-2009). Next, he moved to Massachusetts Institute of Technology (MIT) as a Fulbright Postdoctoral Fellow with Professor Stephen L. Buchwald. At MIT, he worked at the MIT-Novartis Center for Continuous Manufacturing. He currently holds a position as an associate professor in the Micro Flow Chemistry & Process Technology group at Eindhoven University of Technology. His research interests are flow chemistry, homogeneous and heterogeneous catalysis and organic synthesis.

Lecture: “Innovation in synthetic methodology through use of flow”

Craig Johnston
Industry Director – CMAC
Panel discussion moderator

Nick Thomson
Senior Director, Chemical Research and Development, Pfizer Inc.

Biography
Nick graduated from the University of Edinburgh with a BSc (Hons) in Environmental Chemistry before completing a PhD in organic synthesis under Prof. Gerry Pattenden at the University of Nottingham. Nick worked briefly at Zeneca Fine Chemicals Manufacturing Organization, Grangemouth (UK) and joined Pfizer in 1997 as a synthetic chemist in Process Research & Development. Nick spent his early Pfizer career in the evolving process chemistry departments in Sandwich (UK), Sittingbourne (UK) and Holland, Michigan (USA). From 2005 to 2010, Nick led the Sandwich Research Active Pharmaceutical Ingredient (API) department, with accountability for delivery of API technology from lead development to proof of concept. In 2011, Nick joined the Pfizer Chemical Research and Development department in Groton, Connecticut (USA), as a Director of API Process Chemistry Laboratories, with accountability for the Quality by Design development and submission of late stage candidates. In 2014, Nick became head of the Technology API line for Pfizer Chemical Research and Development, with accountability for Technology Strategy, High Throughput Screening, Biocatalysis and Flexible API Supply Technologies (Continuous). Nick has been active in cross pharmaceutical precompetitive collaboration, as Chair of the IQ API Leadership Team and a board member of the Enabling Technologies Consortium.

Nick and his wife Jill have two children, Ben (fifteen) and Anna (thirteen) and live in East Lyme, Connecticut, close to the beach. In his spare time, Nick enjoys oil painting. He coaches youth soccer and is a South Eastern Connecticut Junior Soccer Association trained youth coach and referee. Nick is a board member for the East Lyme Soccer Association and is the Girls Coordinator, accountable for delivery of the girl’s youth soccer program in East Lyme.

Lecture: “Flexible API Supply Technologies (FAST); Continuous Technologies for Greater Agility in API Development and Manufacturing”

Heidrun Gruber-Woelfler
Graz University of Technology
Hands-on course Instructor

Biography

Assoc.Prof. Heidrun Gruber-Woelfler studied technical chemistry at Graz University of Technology, Austria with a focus on chemical engineering. After her PhD dealing with organometallic catalysis, she did her Post-Doc in the area of continuous processes for the synthesis and purification of active pharmaceutical ingredients and finished her habilitation (venia docendi) in the field of Pharmaceutical Engineering in 2018.

Since 2007 she is the head of the research group “Continuous Processes” at the Institute of Process and Particle Engineering, Graz University of Technology and since July 2017 Deputy Director of the Center of Continuous Flow Synthesis and Processing (CCFlow) in Graz. Her current projects deal with heterogeneous (bio)catalysis for API synthesis, continuous processes, reactor design including additive manufacturing as well as in-line analyses.

Thomas McGlone
Technical Operations Manager – CMAC

Biography

Chemistry MSci Graduate from the University of Glasgow. He also completed his PhD at Glasgow under the supervision of Professor Lee Cronin within the area of inorganic synthesis, crystallisation and characterisation. Thomas joined CMAC in 2011 as a knowledge exchange postdoctoral researcher, working with Fujifilm and Syngenta. He then worked with the CMAC Tier 1 companies, GSK, Novartis and Astrazeneca on the Exquisite particles project. All of these projects investigated the feasibility of moving from batch to continuous crystallisation including practical aspects such as fouling. Thomas then joined the core Phase II CMAC centre programme, working to develop a workflow for the design of a continuous crystallisation process. An additional interest is process analytical technology and how this can be applied to monitor crystallisation processes.

Thomas is now the Technical Operations Manager for the CMAC National Facility and is responsible for managing the instrument scientists and research technician team, health and safety, and overseeing CMAC’s multi-million pound asset base.

Xiongwei Ni
Chief Science Director – NiTech Solutions Ltd

Biography

Professor Xiongwei Ni was involved in the development of oscillatory flow technology at its inception in 1988 at the University of Cambridge, UK. He has over 20 years’ research experience and the world expert in the science and technological applications of oscillatory baffled reactors (OBR).

Xiongwei obtained his first degree in Chongqing University, China in 1982, his PhD degree in Leeds University, UK in 1986. He was then a postdoc at Edinburgh and Cambridge Universities, UK. Xiongwei has been a Full Professor in Chemical Engineering at Heriot-Watt University, Edinburgh since August 1999, is the lead author or principal co-author of over 230 scientific papers on OBR related research as well as 8 patents. He was the keynote speaker at American Institute of Chemical Engineering Annual Meetings, Process Intensification Conferences, Scientific Update Conferences, Industrial Seminars of Process Engineering, Society of Chemical Industry Symposium and the Royal Society of Chemistry Symposiums. He delivered over 160 invited seminars at Universities and industries in the USA, France, Germany, the Netherlands, Belgium, Spain, Portugal, Finland, Sweden, Norway, Denmark, Hungary, Israel, UK, Ireland, Canada, Australia, New Zealand, China and Japan.

In 2001, Xiongwei was elected as a Fellow of Institute of Chemical Engineers (FIChemE) and in 2014 a Fellow of the Royal Society of Chemistry (FRSC). Xiongwei has been one of the two UK representatives in Process Intensification in the European Federation of Chemical Engineering since 2005.

In 2005 Xiongwei span off a company, NiTech Solutions Ltd, which specializes continuous reactions and crystallization, has directly involved in a large number of synthesis and crystallization of APIs, fine chemicals and food products, and has gained significant insights into these types of operation. He serves the role of chief science director.

Lecture: Continuous hydrogenation of 3-Butyn-2-ol over Pd/Al2O3 in a Continuous Oscillatory Baffled Reactor

Matthew M. Bio
President & CEO, Snapdragon Chemistry, Inc.

Biography

Dr. Matthew Bio is President & CEO at Snapdragon Chemistry. Matthew began his career in chemistry more than 20 years ago developing continuous processes for the manufacture and purification of acrylates at the former Rohm & Haas company.  Matthew then moved to Columbia University and earned a PhD in Chemistry.  Upon graduating, Matthew returned to industry as a process development chemist at Merck Research Laboratories.  In 2006 Matthew moved to Amgen where he was Director of Process Development.  At Amgen, Matthew led the development of both batch and continuous processes for clinical candidates and drove innovation in technologies for the manufacture of synthetic – biologic hybrid molecules.  In 2015, Matthew joined Snapdragon Chemistry, Inc., a contract development firm specialized in the design of continuous manufacturing technology.  Throughout his career, Matthew has been involved in the development of more than 50 clinical candidates and the launch of three new drugs to the market.  He is author or inventor on more than 30 peer reviewed publications and patents and numerous regulatory filings.  Matthew is driven by a passion for the development of new technologies in organic synthesis to enable safer, more efficient processes and providing access to new chemical architectures.

Lecture to be defined